Semax: A Research Overview of the ACTH(4-7) Analog in 2026

Semax is the second well-characterized product of the synthetic regulatory peptide program run at the Institute of Molecular Genetics of the Russian Academy of Sciences. Like Selank, it takes a short fragment of a larger endogenous molecule and appends a Pro-Gly-Pro cap to protect it from peptidase degradation. Unlike Selank, its parent molecule is a pituitary hormone, and the design decision behind the fragment selection is the most interesting thing about the compound.

For in-vitro laboratory research use only. Not for human consumption.

Separating Two Activities in One Hormone

Adrenocorticotropic hormone is a 39-amino-acid peptide released from the anterior pituitary. Its most familiar function is endocrine: it acts at the melanocortin-2 receptor on the adrenal cortex to stimulate glucocorticoid synthesis and release. That is the hypothalamic-pituitary-adrenal axis function that appears in every physiology textbook.

ACTH also has activities in the central nervous system that are not explained by adrenal stimulation. Work through the 1970s and 1980s examined ACTH and fragments of it in rodent behavioral paradigms and in cultured neurons, and found that the central activities remained measurable in adrenalectomized animals, where the endocrine pathway is unavailable. The central activity was therefore not downstream of glucocorticoid release.

That observation set up a specific structure-activity problem: could the neurotropic activity be separated from the corticotropic activity? If a fragment retained the central nervous system activity while losing the ability to stimulate the adrenal cortex, it would be a considerably cleaner experimental tool than the parent hormone.

Systematic fragment work identified the region around residues 4–10 as carrying the behavioral activity, and the corticotropic activity as requiring the basic residues at positions 15–18 that engage the melanocortin-2 receptor. The tetrapeptide ACTH(4-7) — Met-Glu-His-Phe — retained the central activity measured in the assays used and had no measurable corticotropic activity. It also had a functional half-life of well under a minute.

Semax is ACTH(4-7) with the Pro-Gly-Pro stabilizing extension.

Structure

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, with a molecular weight near 814 g/mol. The first four residues are the ACTH fragment; the last three are the cap shared with Selank.

Structural features that matter for experimental work:

• Methionine at the N-terminus. The thioether side chain of methionine is the most readily oxidized functional group in the molecule. Oxidation to methionine sulfoxide adds 16 Da and is the single most common degradation product observed in Semax preparations. It occurs on exposure to air, to trace metal ions, and to peroxides, and it accumulates over time in improperly stored material.
• Histidine. The imidazole side chain has a pKa near 6.0, meaning its protonation state changes across the physiological pH range. This makes the molecule's net charge pH-sensitive in a way that most short peptides are not, which matters for ion-exchange behavior.
• Glutamate and the two basic-adjacent residues. The peptide carries both acidic and basic character, and its isoelectric point falls in a range where solubility can be reduced.
• Phenylalanine. Provides weak but usable UV absorbance around 257 nm; combined with histidine, the molecule has more chromophore than Selank does, though still far less than a tryptophan-containing peptide.
• Three prolines. As with Selank, the high proline content imposes polyproline-II character and produces cis-trans isomerization behavior visible in chromatography.

Mechanistic Research Domains

The published in-vitro and animal literature on Semax spans several systems. The summaries below describe what has been measured and why it is of mechanistic interest; they are not claims about any effect in people.

Neurotrophin Expression

The most substantial body of Semax research concerns brain-derived neurotrophic factor and nerve growth factor. Dolotov and colleagues (2006) measured BDNF expression in rat hippocampus after Semax exposure, at the transcript level within a short window and at the protein level afterwards.

Subsequent work extended these measurements to NGF and to the receptor side of the system — TrkA and TrkB expression — asking whether the relationship is limited to ligand availability or includes the signaling apparatus that receives it. Studies in cultured neurons have examined neurite outgrowth and survival under conditions of trophic factor withdrawal, which are the standard in-vitro assays of neurotrophin research.

The neurotrophin hypothesis is of interest because it offers a mechanistic bridge between a short peptide with no identified receptor and the longer-lasting changes measured in animal studies. BDNF-TrkB signaling drives structural synaptic plasticity, and changes at that level persist long after the initiating stimulus has cleared.

Monoaminergic Signaling

Semax has been examined in relation to dopaminergic and serotonergic transmission, with studies measuring dopamine turnover in striatal tissue and serotonin metabolism in cortical and hippocampal regions. As with Selank, the reported measurements vary with region and with the baseline state of the system, a pattern more consistent with modulation of existing tone than with unidirectional drive.

Some work has examined interactions with the endogenous opioid system, including measurements of enkephalin-degrading enzyme activity analogous to those described for Selank. The shared Pro-Gly-Pro cap is a plausible common factor here, and this is one of the cases where running both peptides in parallel is informative.

Gene Expression in Experimental Ischemia Models

A portion of the Semax literature uses experimental models of cerebral ischemia in rodents, most commonly middle cerebral artery occlusion. These models allow tissue-level measurements such as lesion volume, histology, and markers of inflammation in peri-lesional tissue.

Medvedeva and colleagues (2014) approached this with transcriptome profiling, characterizing gene expression in rat brain after an ischemic insult with and without Semax exposure. The reported pattern involved immune and inflammatory gene clusters rather than a small number of individually large changes — the same distributed pattern seen in the Selank transcriptome work, and a pattern that argues for gene-set-level analysis in future studies of this class.

Behavioral Paradigms in the Fragment Tradition

Rodent studies have examined Semax in avoidance and maze-based paradigms, including passive avoidance, active avoidance, and spatial tasks. This line of work is a direct methodological descendant of the original ACTH fragment behavioral studies from the 1970s and 1980s, and it uses many of the same paradigms.

Methodologically these studies carry the usual caveats of rodent behavioral research: measurements in avoidance paradigms are sensitive to shock intensity, handling, and stress state, and a change in a proxy measure does not straightforwardly map onto an underlying construct. Studies that include locomotor and nociceptive controls are considerably more interpretable than those that do not.

Semax and Selank Compared

The shared cap means shared handling characteristics and a shared set of analytical challenges from the proline content. The active fragments engage entirely different systems.

Analytical Verification

Purity by reverse-phase HPLC. The COA should report the HPLC purity together with the chromatogram itself. As with any proline-rich peptide, cis-trans isomerization can broaden peaks; elevated column temperature or orthogonal MS confirmation distinguishes conformational broadening from genuine heterogeneity.

The oxidation peak. This is the analysis point specific to Semax. Methionine sulfoxide is more polar than methionine and elutes earlier on reverse-phase columns, typically as a shoulder or a resolved peak just ahead of the main product. A certificate showing a small early-eluting peak in a Semax chromatogram is very likely showing partial oxidation. Mass spectrometry confirms it: the oxidized species is exactly 16 Da heavier. A supplier that reports only a purity percentage, without the chromatogram, makes this invisible to the buyer.

Identity by mass spectrometry. Theoretical and observed masses should both be stated. Beyond the +16 oxidation signature, the informative differences are deletion sequences from incomplete proline couplings.

UV detection wavelength. Phenylalanine and histidine give weak absorbance near 257 nm, but HPLC detection for this peptide is normally at 214–220 nm on the peptide bond. Quantification by absorbance is not reliable; amino acid analysis or corrected gravimetry should be used.

Counterion and net peptide content. TFA counterions from reverse-phase purification contribute meaningfully to gross weight. Molar concentration calculations should use net peptide content.

A note on why storage discipline matters more for this compound than for most: methionine oxidation is a slow, cumulative, and entirely invisible process. There is no colour change, no precipitation, and no odour to signal it. A vial that has spent months in a frost-free freezer — where the automatic defrost function repeatedly warms the contents — can carry a substantially higher sulfoxide fraction than the certificate of analysis describes, while looking identical to a properly stored vial. Laboratories running long studies with a single lot should therefore treat re-verification partway through as routine rather than exceptional, and should record the storage unit type in their methods. Where a manual-defrost freezer is available, it is preferable to a frost-free unit for this class of material, and a temperature logger on the unit converts an assumption about storage conditions into a documented fact.

Handling and Storage

Lyophilized Semax should be stored at -20°C, protected from light and moisture, and kept lyophilized until required.

The oxidation liability explains most of the handling considerations:

• Minimize headspace and air exposure. Opening a vial repeatedly introduces oxygen each time; a single aliquoting operation when a stock solution is first prepared is preferable to repeated access.
• Trace metals matter. Copper and iron ions catalyze methionine oxidation.
• Peroxides oxidize methionine. Ethers in particular accumulate peroxides on storage.
• Protect from light and keep cold during any working session.
• Avoid repeated freezing and thawing of prepared solutions.

This site does not publish solution-preparation instructions, concentration guides, or usage instructions of any kind. Those determinations belong to the researcher working under an approved study plan in a properly equipped laboratory.

Experimental Readouts Used in Semax Studies

BDNF and NGF quantification. ELISA for protein in tissue homogenate, quantitative PCR for transcript. Measuring both is important because the two respond on different timescales and neurotrophin expression is heavily post-transcriptionally regulated.

Receptor expression. TrkA, TrkB, and p75NTR levels by immunoblot or qPCR. A change in ligand without a change in receptor implies a different mechanistic picture than coordinated change in both.

Neurite outgrowth in culture. Length, branching, and the proportion of neurite-bearing cells in primary neuronal or PC12 cultures, quantified by automated image analysis. This is the workhorse in-vitro neurotrophic assay and provides a cell-autonomous readout independent of systemic effects.

Trophic withdrawal survival assays. Culturing neurons in the absence of their required trophic factor and measuring survival with and without the test compound separates survival-related measurements from growth-related ones.

Lesion volume in ischemia models. Triphenyltetrazolium chloride staining of serial brain sections, with volumes corrected for edema. Correction is essential — uncorrected volumes systematically overestimate lesion size because swelling inflates the measured area.

Neurological deficit scoring. Composite scales assessing forelimb flexion, circling behavior, and reflex responses. These require blinded scoring; the effect sizes reported in unblinded studies in this literature are systematically larger.

Monoamine and metabolite quantification. HPLC with electrochemical detection on dissected regions, or microdialysis in freely moving animals.

Transcriptome profiling. Gene-set-level analysis is generally more informative than individual-gene analysis for this compound class, given the distributed pattern of modest changes.

Common Pitfalls in Semax Experimental Design

Not checking oxidation state before use. This is the pitfall specific to Semax. Material that was highly pure at manufacture can accumulate a meaningful fraction of methionine sulfoxide over months of imperfect storage. Two laboratories using the same nominal compound from the same original lot can be working with materially different mixtures. Where a study spans a long period, re-verification partway through is prudent.

Assuming corticotropic activity is fully absent. The fragment was selected because it lacked measurable adrenal stimulation in the assays used at the time. In a study where HPA axis activation is a possible confound, measuring corticosterone directly is a small addition that removes the ambiguity.

Comparing across preparation methods. Semax solutions prepared in buffers of different pH, with or without chelators, or stored for different periods before use differ in oxidation state and in histidine protonation. They are not equivalent inputs, and measurements do not transfer between them.

Treating BDNF transcript change as BDNF protein change. They are different measurements on different timescales, and the inference from one to the other is reasonable but should be stated as an inference rather than a finding.

Omitting behavioral controls. Behavioral paradigms in rodents are sensitive to arousal, locomotion, and nociception. Without controls for these, an apparent change in a task measure cannot be distinguished from a change in motivation or sensitivity.

Grouping with Selank by provenance. The two compounds share a design origin and a stabilizing cap, not a mechanism. Literature reviews that treat them as one class are grouping by history rather than pharmacology.

Search-term incompleteness. As with Selank, much of the primary literature originated in Russian-language journals with variable indexing. Searching only "Semax" in English-language databases returns an incomplete slice of the field; searching the ACTH(4-7) descriptors returns additional work, including the older fragment studies that established the structure-activity basis for the compound.

Reading the Semax Literature Critically

The Semax literature has a distinctive shape, and knowing that shape helps in weighting individual studies.

It has three eras. The earliest layer is the ACTH fragment structure-activity work of the 1970s and 1980s, which predates Semax itself and establishes why the 4-7 fragment was chosen. The middle layer is the 1990s and 2000s Russian-language mechanistic work that characterized the stabilized compound. The most recent layer is international work, often using modern molecular tools, that revisits the mechanistic claims. Studies from different eras use different methods and different reporting standards, and a citation from one era does not validate a claim made in another.

The literature spans several national research traditions. Studies conducted in different countries follow different design and reporting conventions, so researchers citing the literature should state which body of work a claim comes from. In the United States Semax is not approved for human or veterinary use and is supplied for in-vitro laboratory research only.

Ischemia model heterogeneity. Middle cerebral artery occlusion can be permanent or transient, filament-based or embolic, and each variant produces a different lesion with different time courses of injury and inflammation. Lesion volume measurements are not comparable across variants. Studies should state the model precisely, and reviews that pool across variants are averaging over meaningfully different biology.

Effect sizes and blinding. In the neurological deficit scoring literature generally, unblinded studies report larger effects than blinded ones. Where a Semax study does not state its blinding procedure, the reported effect size should be treated as an upper bound.

Preparation details again. As noted, how a solution was prepared and stored affects its oxidation state. A study that does not report preparation and storage conditions cannot be directly compared with one that does, and should not be cited as a replication of it.

The Pro-Gly-Pro Cap as an Experimental Variable

The C-terminal extension shared with Selank was added for pharmacokinetic reasons, but it is not pharmacologically silent and should not be described as if it were.

The cap roughly doubles the molecular weight of the active fragment, imposes polyproline-II conformational character on a chain that would otherwise be flexible, and changes the hydrodynamic and charge properties of the molecule. Several consequences follow.

Semax is not simply "stable ACTH(4-7)." Its activity profile overlaps that of the free fragment but is not identical. Studies that cite free-fragment data as evidence for a Semax mechanism are making an assumption the structural change does not license. Where the distinction matters, both compounds should be run.

The Pro-Gly-Pro tripeptide has been examined in its own right. Whether it is released intact during metabolism of Semax, and whether any released fragment contributes to observed effects, is a question most studies do not address. It should be held open as an explanation for unexpected findings.

Rigidity constrains induced fit. A polyproline-II rod loses less conformational entropy on binding than a flexible chain, which generally favors association, but it also cannot adopt bent conformations that a flexible peptide could. Where the ACTH(4-7) core would need to flex to engage a site, the capped version may not be able to.

The cap is the basis for the Selank comparison. Because both compounds carry it, effects common to both are candidates for cap-attributable or handling-attributable phenomena, and effects unique to one are candidates for active-fragment-attributable mechanism. This is the strongest reason to run the two together rather than separately.

Why Synthesis Quality Matters More Than Usual Here

Semax combines two independent manufacturing liabilities in a seven-residue chain, which is unusual and which makes analytical documentation more valuable than it would be for a routine peptide.

The oxidation-sensitive residue sits at the N-terminus. Methionine at position one is exposed throughout synthesis, cleavage, purification, and lyophilization. Cleavage cocktails for methionine-containing peptides require appropriate scavengers; omitting them, or using a cocktail past its usable life, produces material that is partially oxidized before it is ever bottled. Because methionine sulfoxide is only 16 Da heavier and only modestly more polar, a steep gradient will bury it under the main peak and a summary purity number will not show it.

The proline-rich C-terminus is coupling-hostile. Three prolines mean multiple sterically hindered couplings in a short chain. Incomplete coupling produces deletion sequences 97 Da lighter than target. These are readily detected by mass spectrometry and less reliably by chromatography alone.

Histidine racemization risk. Histidine is among the residues most prone to racemization during activation, particularly under prolonged coupling conditions or with certain activator chemistries. The D-histidine-containing epimer has identical mass and near-identical retention behavior on achiral columns, so it will not be detected by the standard analytical package at all. Manufacturers who control this use appropriate side-chain protection and minimize activation time; buyers cannot verify it from a routine certificate, which is a reason to weight manufacturer track record alongside documentation.

C-terminal chemistry. The specification must be met exactly, since resin choice and cleavage conditions determine whether the product terminates in an amide or a free acid — a one-Dalton, one-charge difference that changes electrostatic interactions.

The practical conclusion is the same as for other structurally demanding peptides: a percentage is not documentation. The chromatogram shape, the numeric mass comparison, and the method details all carry information the summary number does not.

Where Semax Fits Among Research Tools

Semax is most useful experimentally as a probe for neurotrophin-mediated plasticity — a short, stable, synthetically accessible molecule whose relationship to BDNF and NGF expression has been measured repeatedly in rodent models. Small synthetic peptides studied in this way, without being neurotrophins themselves, are scarce, and that scarcity is what gives Semax its niche.

The natural pairing is with Selank. The two share the Pro-Gly-Pro cap, the handling profile, and the synthesis challenges from proline content, while engaging unrelated systems through their active fragments. Running both allows a study to separate scaffold and handling effects from active-fragment effects, which is a control that cannot be constructed with either compound alone. Researchers working on mitochondrial contributions to neuronal function sometimes extend the panel with SS-31, which is used to study inner-membrane organization rather than trophic signaling.

Sourcing Considerations

Semax has a manufacturing profile that rewards careful supplier selection.

The methionine problem is a manufacturing problem before it is a storage problem. Oxidation can occur during synthesis, during the cleavage step, during purification, and during lyophilization. A manufacturer working under nitrogen with degassed solvents and appropriate scavengers in the cleavage cocktail produces material with a low starting sulfoxide fraction; one that does not produces material that is already partially oxidized on the day it is bottled. The purity number alone will not reveal this if the oxidized species is not resolved from the main peak, which is why the chromatogram matters.

Proline coupling deletions. Three prolines in seven residues means multiple sterically hindered couplings. Under compressed schedules, incomplete coupling produces truncated sequences differing by 97 Da — clearly resolved by MS, less reliably resolved by a steep HPLC gradient.

Free acid versus amide. The C-terminal chemistry must match the specification. Resin choice and cleavage conditions determine it, and the difference is one Dalton plus a charge.

What to require from a supplier:

• Independent third-party analysis from a laboratory with no stake in the outcome of the analysis.
• Both HPLC and MS on the same sample, with theoretical and observed masses stated numerically.
• The chromatogram itself, so the region just ahead of the main peak can be inspected for the oxidation shoulder.
• Named laboratory and method details, so the separation conditions can be judged.
• Counterion disclosure, with acetate exchange available where the application requires it.
• Frozen storage before dispatch and a short, tracked transit, since sustained heat accelerates oxidation as well as general degradation.

Excalibur Peptides supplies Semax as a lyophilized research material shipped from the United States, and a Certificate of Analysis is published for this product. It is available on the Semax product page and in the COA database, so the analytical data can be reviewed before purchase.

Regulatory Status

Semax is not approved by the FDA for any human use. The material described in this article is sold as a laboratory reagent for in-vitro research and identification purposes only, under a research-use-only designation that buyers certify at checkout. Nothing in this overview describes or implies any use in people or animals. Researchers should confirm any institutional requirements for the purchase, storage, and disposal of research chemicals before ordering.

Frequently Asked Questions

What is Semax?

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) consisting of the ACTH(4-7) fragment with a Pro-Gly-Pro stabilizing extension. It has been examined in published in-vitro and animal research on BDNF and NGF expression and monoamine signaling. It is supplied strictly for in-vitro laboratory research and is not for human consumption.

What is Semax derived from?

Semax is based on residues 4 through 7 of adrenocorticotropic hormone. That fragment retains the central nervous system activity described for the parent hormone in animal research while lacking the corticotropic activity, which requires basic residues located further along the ACTH sequence.

How is Semax different from Selank?

Both share the Pro-Gly-Pro stabilizing cap and originated in the same research program, but their active fragments are unrelated. Semax is built on ACTH(4-7) and has been studied mainly in relation to BDNF and NGF expression; Selank is built on tuftsin and has been studied mainly in relation to GABAergic and immune signaling.

Why is methionine oxidation a concern with Semax?

The N-terminal methionine residue oxidizes readily to methionine sulfoxide, adding 16 Da and producing an earlier-eluting species on reverse-phase HPLC. This can occur during manufacture or during storage, so both the chromatogram and appropriate cold, light-protected, low-oxygen storage matter for this compound.

What analytical documentation is relevant for Semax?

Reverse-phase HPLC with the chromatogram shown, so the region just ahead of the main peak can be checked for methionine sulfoxide, and mass spectrometry reporting the observed mass alongside the theoretical mass, both from a named laboratory. A Certificate of Analysis is published for the Excalibur Peptides Semax product.

Is Semax approved for human use?

No. Semax is sold strictly for in-vitro laboratory research and identification purposes. It is not approved for human or veterinary use, is not for human consumption, and is not intended for any clinical application.

View the Semax product page · View the Selank product page · Browse the research catalog · View the COA database

All compounds referenced in this article are sold for in-vitro laboratory research purposes only. They are not approved by the FDA for human or veterinary use and are not intended for human use, veterinary use, or consumption of any kind. Always consult applicable regulations regarding peptide research in your jurisdiction.

Last updated: October 2026